The ATLAS ACS-2 trial tested the use of rivaroxaban in addition to standard dual antiplatelet therapy in patients with acute coronary syndrome. The results showed a reduction in the composite of CV mortality, recurrent MI, and stroke, but increased the risk of nonfatal bleeding.

2012, ATLAS ACS-2 Trial Visual Abstract: Rivaroxaban after ACS, NEJM